Amicus' press releases are available at http://www.amicustherapeutics.com
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.
This Press release contains and the accompanying conference call will
contain "forward-looking statements" within the meaning of Section 21E of
the Private Securities Litigation Reform Act of 1995. Words such as, but
not limited to, "look forward to," "believe," "expect," "anticipate,"
"estimate," "intend," "plan," "targets," "likely," "will," "would,"
"should" and "could," and similar expressions or words identify
forward-looking statements. Examples of such statements include: (i)
statements regarding the goals and expected timing of clinical studies,
including the effect of the completion of the Phase 2 clinical trial for
Amigal for the treatment of Fabry disease, the timing and design of Phase 3
clinical development for Amigal, the Phase 2 clinical trials for Plicera
for the treatment of Gaucher disease, the effect of
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved